# Thymosin β4

Thymosin β4 has 18 registered human trials. It is marketed for 4 different uses.

**In short**

- 18 registered human trials exist for Thymosin β4.
- Thymosin β4 is not FDA-approved for any use.
- What has actually been studied: myocardial infarction, myocardial ischemia, pressure ulcers.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Tissue repair
- Wound healing
- Hair growth
- Cardiac recovery

## What has actually been tested

- Myocardial Infarction
- Myocardial Ischemia
- Pressure Ulcers
- Atherosclerotic Cardiovascular Diseases
- Endothelial Dysfunction
- Dry Eye Syndrome
- Acute Myocardial Infarction
- ST Elevation Myocardial Infarction
- STEMI
- Healthy
- Venous Stasis Ulcers
- Dry Eye Syndromes
- Dry Eye
- Neurotrophic Keratopathy
- Sjogren's Syndrome
- Graft vs. Host Disease
- Epidermolysis Bullosa
- Diabetes
- Acute Myocardial Infarction (AMI)
- Acute Myocardial Infarction of Anterior Wall
- Acute Myocardial Infarction With ST Elevation
- Acute Myocardial Infarction of Left Ventricle
- Acute Myocardial Infarction With ST Segment Elevation

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT00743769](https://clinicaltrials.gov/study/NCT00743769) | A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers | Myocardial Infarction, Myocardial Ischemia | Phase 1 | WITHDRAWN | 0 |
| [NCT00382174](https://clinicaltrials.gov/study/NCT00382174) | Study of Thymosin Beta 4 in Patients With Pressure Ulcers | Pressure Ulcers | Phase 2 | COMPLETED | 72 |
| [NCT07487363](https://clinicaltrials.gov/study/NCT07487363) | TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 2 | RECRUITING | 80 |
| [NCT02974907](https://clinicaltrials.gov/study/NCT02974907) | Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2 | Dry Eye Syndrome | Phase 3 | COMPLETED | 601 |
| [NCT01311518](https://clinicaltrials.gov/study/NCT01311518) | A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction | Acute Myocardial Infarction, ST Elevation Myocardial Infarction | Phase 2 | WITHDRAWN | 0 |
| [NCT04555824](https://clinicaltrials.gov/study/NCT04555824) | A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers | Healthy | Phase 1 | COMPLETED | 54 |
| [NCT05984134](https://clinicaltrials.gov/study/NCT05984134) | Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction | Acute Myocardial Infarction | Phase 2 | COMPLETED | 90 |
| [NCT04555850](https://clinicaltrials.gov/study/NCT04555850) | A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers | Healthy | Phase 1 | COMPLETED | 30 |
| [NCT00832091](https://clinicaltrials.gov/study/NCT00832091) | Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers | Venous Stasis Ulcers | Phase 2 | COMPLETED | 72 |
| [NCT03937882](https://clinicaltrials.gov/study/NCT03937882) | Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 | Dry Eye Syndromes, Dry Eye | Phase 3 | COMPLETED | 700 |
| [NCT02597803](https://clinicaltrials.gov/study/NCT02597803) | Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 | Dry Eye Syndrome | Phase 3 | COMPLETED | 317 |
| [NCT05555589](https://clinicaltrials.gov/study/NCT05555589) | Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 | Neurotrophic Keratopathy | Phase 3 | RECRUITING | 70 |
| [NCT05485818](https://clinicaltrials.gov/study/NCT05485818) | Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction | Acute Myocardial Infarction | Phase 2 | COMPLETED | 62 |
| [NCT01387347](https://clinicaltrials.gov/study/NCT01387347) | Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye | Dry Eye Syndrome, Dry Eye | Phase 2 | COMPLETED | 72 |
| [NCT01393132](https://clinicaltrials.gov/study/NCT01393132) | Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye | Dry Eye, Sjogren's Syndrome | Phase 2 | COMPLETED | 9 |
| [NCT00311766](https://clinicaltrials.gov/study/NCT00311766) | A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa | Epidermolysis Bullosa | Phase 2 | TERMINATED | 30 |
| [NCT00598871](https://clinicaltrials.gov/study/NCT00598871) | A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds | Diabetes | Phase 2 | TERMINATED | 12 |
| [NCT07586865](https://clinicaltrials.gov/study/NCT07586865) | Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction | Acute Myocardial Infarction (AMI), Acute Myocardial Infarction of Anterior Wall | Phase 2 | NOT_YET_RECRUITING | 189 |

## Common questions

**How many human trials does Thymosin β4 have?**
18, each listed above with a link to its original record.

**Is Thymosin β4 FDA approved?**
No. It is not approved by the FDA for any indication.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/thymosin-beta-4*